03.11.2022 - IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the third quarter ended September 30, 2022 and provided a general business update. “With the positive data from our GATHER2 clinical trial reported in the third .
MeiraGTx Holdings plc (MGTX) ReportS Strong Phase 1/2 Data for Botaretigene Sparoparvovec streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CHICAGO — A new diagnostic scale correlated with best corrected visual acuity and could serve as an alternative to evaluate disease activity in neovascular age-related macular degeneration, according to a study.
Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial.